The SUMMIT Newsletter issued periodically provides information on SUMMIT community and its most
Newsletter & Flyer
5th SUMMIT Newletter!
This issue informs you about IMI2 and Horizon 2020, it reports on the IMI Diabetes Platform Symposium in Barcelona and has some exciting interviews with SUMMIT partners on their discoveries on plaque imaging and on atherosclerosis.
Enjoy the read of the 5th issue of our newsletter!
3th SUMMIT Newsletter!
This issue informs you on the CVD workshop held in Malmö on 8 May. It emphasizes the objectives, a range of brainstorming ideas discussed by participants and the time lines set for the coming months. Apart from this activity, the newsletter also announces exciting news on SUMMIT members.
Enjoy the read of the 3rd Issue of our newsletter!
2nd SUMMIT Newsletter!
A significant part of this issue content brings attention to the 4th SUMMIT Annual Meeting held in Biberach 27-28 February. The newsletter also details the most recent publications being put forth by the SUMMITcommunity so as to communicate its research achievements.
Enjoy the read of the 2nd Issue of our newsletter!
1st SUMMIT Newsletter!
The newsletter will be published several times a year. Its creation is motivated by the intent to familiarize public and private stakeholders with SUMMIT initiatives and enrichment strategies to combat diabetes complications. Because there are more than 100 experts working on SUMMIT project, the newsletter is also of great value in raising awareness of what is going on within the SUMMIT community.
Enjoy the read of the 1st Issue of our newsletter!
The IMI Diabetes Platform :Collaborative approaches to overcome key bottlenecks on the way to novel therapies
A state-of-the-art flyer titled "The IMI Diabetes Platform" was released together with the colleagues from the two other IMI diabetes calls, IMIDIA and DIRECT.
The flyer is designed to give both good visibility to each single consortium and at the same time a good understanding of those aspects of IMI diabetes research that together constitute one of the most holistic discovery approaches in diabetes so far.
The IMI diabetes flyer highlights unique selling points and addresses those with a special interest in IMI diabetes projects, e.g. academia, pharma, the EC and other stakeholders like country organisations or member state groups, clinicians, patients, economists, national authorities as well as patient organisations.
The flyer was first presented to a broad public audience at the 2012 EASD annual meeting in Berlin via the EASD information booth and SUMMIT EFPIA participant stands at the exhibition.
4th SUMMIT Newsletter!
This issue highlights the forthcoming EASD meeting and the 1-st joint satellite symposium of the IMI Diabetes Platform, both to be held in Barcelona September 22-27. It also provides an overview of the most recent findings from the SUMMIT community reported under the Hot off the Press section.
Enjoy the read of the 4th Issue of our newsletter!
To DISCOVER, DEVELOP and QUALIFY potential MARKERS that empower:
the identification of patients at high risk of diabetes complications
the monitoring of the complications' progression and patients‘ response to therapy
To use the discovered markers as SURROGATE ENDPOINTS in clinical trials.
Thereby, SHORTEN the long lasting CLINICAL TRIALS to bring about EARLIER availability of NEW THERAPY to diabetic patients.